Advances in drug treatments for mesothelioma-Reference-Cited by-同舟云学术

Advances in drug treatments for mesothelioma

Published:2022-05-09 Issue:8 Volume:23 Page:929-946
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Zucali Paolo Andrea¹²,De Vincenzo Fabio²,Perrino Matteo²,Digiacomo Nunzio²,Cordua Nadia¹,D’Antonio Federica¹,Borea Federica¹,Fazio Roberta¹,Pirozzi Angelo¹,Santoro Armando¹²

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Milan, Italy

2. Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2072211

Reference88 articles.

1. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma

3. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma

4. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

5. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma;Frontiers in Immunology;2023-06-16

2. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress;Frontiers in Immunology;2023-01-27